創興銀行(01111.HK)發行2.5億美元5.5厘無到期日非累計後償額外一級資本證券
創興銀行(01111.HK)公布,該行與中銀國際亞洲有限公司、民銀証券有限公司、招銀國際融資有限公司、中信里昂證券有限公司、越秀証券有限公司、創興銀行有限公司、農銀國際融資有限公司及建銀國際金融有限公司訂立認購協議。根據認購協議,該行將發行 2.5億美元5.5%無到期日非累計後償額外一級資本證券。在達致若干先決條件後,建議發行預計將於2020年8月3日完成。
該行已獲悉,其最終母公司廣州越秀集團股份有限公司擬按與適用於該等證券的所有其他投資者相同的條款及條件認購本金額最多2,500萬美元的證券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.